Endobronchial melanoma of unknown primary, frequently termed ghost melanoma, is an exceptionally rare clinical entity characterized by metastatic malignant melanoma manifesting within the bronchial lumen without a readily identifiable cutaneous, ocular, or mucosal primary lesion, according to case reports published in medical literature such as Cureus. Clinicians often encounter these lesions mimicking primary bronchogenic carcinoma during routine diagnostic workups for persistent respiratory symptoms and abnormal chest imaging.
Clinical Presentation and Diagnostic Challenges
Patients with endobronchial melanoma typically present with nonspecific pulmonary symptoms including cough, hemoptysis, dyspnea, and recurrent obstructive pneumonia. According to diagnostic evaluations outlined in peer-reviewed pulmonary journals, physical examinations frequently fail to reveal suspicious skin lesions or mucosal abnormalities, complicating the clinical picture. Chest computed tomography (CT) scans usually demonstrate a centrally located endobronchial mass causing bronchial stenosis or atelectasis, which is radiologically indistinguishable from primary non-small cell lung cancer. Consequently, definitive diagnosis relies heavily on bronchoscopic biopsy combined with immunohistochemical staining.
Pathological Confirmation and Immunohistochemistry
Histological examination is mandatory to differentiate metastatic melanoma from primary pulmonary malignancies and other endobronchial tumors. According to pathology guidelines from institutions such as the College of American Pathologists, tumor cells often display characteristic pigmentation, though amelanotic variants do occur. Immunohistochemical panels are critical for confirmation; metastatic melanoma typically tests positive for specific melanocytic markers including S100 protein, Melan-A (MART-1), HMB-45, and SOX10, while testing negative for epithelial markers like cytokeratins. Establishing a primary site requires exhaustive dermatological, ophthalmologic, and ear, nose, and throat (ENT) examinations to rule out a regressed or occult primary lesion elsewhere in the body.
Management Strategies and Prognosis
Therapeutic approaches for endobronchial melanoma of unknown primary depend heavily on the extent of disease at the time of detection. According to clinical oncology reviews, localized endobronchial lesions are managed primarily with surgical resection, such as lobectomy or sleeve resection, when patients can tolerate the procedure and distant metastases are absent. For patients with unresectable or disseminated disease, systemic therapies including immune checkpoint inhibitors—such as anti-PD-1 and anti-CTLA-4 monoclonal antibodies—and targeted BRAF/MEK inhibitors have significantly altered treatment paradigms and improved survival outcomes. Despite these advancements, the prognosis for metastatic melanoma involving the respiratory tract remains guarded, necessitating vigilant multidisciplinary follow-up.
Frequently Asked Questions
What is ghost melanoma of the lung?
Ghost melanoma refers to endobronchial metastatic melanoma where the primary tumor site cannot be found, meaning the lesion appears inside the airway without an obvious source on the skin or other organs.
How do doctors diagnose endobronchial melanoma?
Diagnosis requires bronchoscopy with tissue biopsy, followed by specialized immunohistochemical staining to identify specific melanoma markers like S100 and HMB-45.
Is endobronchial melanoma treated the same way as primary lung cancer?
No, treatment protocols differ significantly, as metastatic melanoma relies more heavily on systemic immunotherapy and targeted treatments compared to standard non-small cell lung cancer therapies.